Advac : Advanced Course of Vaccinology - The power and limitations of immunobridging studies: the example of COVID-19 vaccines

The power and limitations of immunobridging studies: the example of COVID-19 vaccines

Discussion topic:
The power and limitations of immunobridging studies: the example of COVID-19 vaccines

Chair: Hanna Nohynek, Finnish Institute for Health and Welfare, Finland and Member of the ADVAC Scientific Committee
Presentations :
Bridging studies – why and how? Peter Dull, Bill & Melinda Gates Foundation Criteria and requirement for the licensing of new vaccines with special emphasis on COVID-19 the view of EMA. Marco Cavaleri, Head of Office Biological Health Threats and Vaccine Strategy, European Medicines Agency.
Panel discussion: Strategies behind the variant adapted COVID-19 vaccines development with participation from regulators, Godwin Enwere, WHO Prequalification Unit, Vikram Paradkar, Executive Vice-President Production, Biological E, representing DCVMN, Jeff Roberts, Associate Vice-President Clinical Research, MSD, representing IFPMA, and other experts.